D.E. Shaw & Co
CCCC icon

D.E. Shaw & Co’s C4 Therapeutics CCCC Stock Holding History

D.E. Shaw & Co’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.13M Buy
1,740,989
+680,658
+64% +$2.33M ﹤0.01% 2006
2026
Q1 		$2.79M Buy
1,060,331
+1,007,452
+1,905% +$2.37M ﹤0.01% 2655
2025
Q4 		$101K Buy
52,879
+41,016
+346% +$97.2K ﹤0.01% 4396
2025
Q3 		$26.3K Sell
11,863
-77,612
-87% -$186K ﹤0.01% 4428
2025
Q2 		$128K Buy
89,475
+10,200
+13% +$14.8K ﹤0.01% 4106
2025
Q1 		$127K Buy
79,275
+2,796
+4% +$8.34K ﹤0.01% 3996
2024
Q4 		$275K Sell
76,479
-42,413
-36% -$211K ﹤0.01% 3937
2024
Q3 		$678K Sell
118,892
-237,320
-67% -$1.43M ﹤0.01% 3520
2024
Q2 		$1.65M Sell
356,212
-140,331
-28% -$837K ﹤0.01% 2832
2024
Q1 		$4.06M Buy
496,543
+252,905
+104% +$1.96M ﹤0.01% 2049
2023
Q4 		$1.38M Sell
243,638
-190,472
-44% -$434K ﹤0.01% 2921
2023
Q3 		$807K Sell
434,110
-85,069
-16% -$259K ﹤0.01% 3182
2023
Q2 		$1.43M Buy
519,179
+325,018
+167% +$1.04M ﹤0.01% 2869
2023
Q1 		$610K Buy
194,161
+108,200
+126% +$637K ﹤0.01% 3453
2022
Q4 		$507K Sell
85,961
-44,121
-34% -$366K ﹤0.01% 3840
2022
Q3 		$1.14M Buy
130,082
+51,294
+65% +$533K ﹤0.01% 3496
2022
Q2 		$594K Buy
+78,788
New +$693K ﹤0.01% 3999
2022
Q1 		– Sell
-25,735
Closed -$829K – 5565
2021
Q4 		$829K Buy
25,735
+15,852
+160% +$627K ﹤0.01% 4085
2021
Q3 		$442K Sell
9,883
-6,649
-40% -$285K ﹤0.01% 4156
2021
Q2 		$626K Buy
16,532
+11,102
+204% +$398K ﹤0.01% 3913
2021
Q1 		$201K Sell
5,430
-7,144
-57% -$284K ﹤0.01% 3853
2020
Q4 		$417K Buy
+12,574
New +$365K ﹤0.01% 3470

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co's CCCC Position: Q2 2026 in Review

D.E. Shaw & Co increased its C4 Therapeutics (CCCC) stake by 64% in Q2 2026, buying an estimated $2.33M and bringing the position to 1,740,989 shares worth $8.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2006.

D.E. Shaw & Co first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • D.E. Shaw & Co held 1,740,989 shares of C4 Therapeutics worth $8.13M as of Q2 2026.
  • D.E. Shaw & Co bought 680,658 C4 Therapeutics shares in Q2 2026, an estimated $2.33M.
  • C4 Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2006 holding.
  • D.E. Shaw & Co first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.